PMID- 11839661
OWN - NLM
STAT- MEDLINE
DCOM- 20020528
LR  - 20061115
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 8
IP  - 2
DP  - 2002 Feb
TI  - The role of retinoid X receptor messenger RNA expression in curatively resected 
      non-small cell lung cancer.
PG  - 438-43
AB  - BACKGROUND: Retinoid X receptors (RXRs) have inhibitory effects on non-small cell 
      lung cancer (NSCLC) cell growth, and RXRbeta expression is reduced in NSCLC 
      specimens compared with normal lung tissue. We hypothesized that suppressed RXR 
      expression might be a prognostic factor of worse clinical outcome in patients 
      with NSCLC. EXPERIMENTAL DESIGN: Using a quantitative real-time reverse 
      transcription-PCR (TaqMan) method, we analyzed RXRalpha, RXRbeta, and RXRgamma 
      mRNA expression in normal lung tissue and matching tumor samples from 88 patients 
      with NSCLC. RESULTS: The median mRNA expression levels of all three RXR subtypes 
      were frequently decreased in tumor tissues compared with matching normal lung 
      tissue (RXRalpha, 67%; RXRbeta, 55%; RXRgamma, 89%). The RXRalpha(P = 0.001) and 
      RXRgamma(P < 0.001) median expression levels were significantly lower in the 
      tumors. Patients whose tumors exhibited low RXRbeta expression levels had a 
      statistically significant worse overall survival (P = 0.0005), whereas a trend 
      toward worse survival was observed for patients with low RXRalpha expression. 
      Multivariate analysis indicated that low RXRbeta expression is an independent 
      predictor of worse survival in patients with NSCLC (P = 0.017). CONCLUSION: 
      Suppressed mRNA expression of all three RXR subtypes is a frequent event in 
      NSCLC. Reduced RXRbeta expression might be an important biomarker for more 
      aggressive disease in patients with NSCLC.
FAU - Brabender, Jan
AU  - Brabender J
AD  - Department of Molecular Biology and Biochemistry, Norris Comprehensive Cancer 
      Center, University of Southern California/Keck School of Medicine, Los Angeles, 
      CA 90033, USA.
FAU - Danenberg, Kathleen D
AU  - Danenberg KD
FAU - Metzger, Ralf
AU  - Metzger R
FAU - Schneider, Paul M
AU  - Schneider PM
FAU - Lord, Reginald V
AU  - Lord RV
FAU - Groshen, Susan
AU  - Groshen S
FAU - Tsao-Wei, Denice D
AU  - Tsao-Wei DD
FAU - Park, JiMin
AU  - Park J
FAU - Salonga, Dennis
AU  - Salonga D
FAU - Holscher, Arnulf H
AU  - Holscher AH
FAU - Danenberg, Peter V
AU  - Danenberg PV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoid X Receptors)
RN  - 0 (Transcription Factors)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/*metabolism/surgery
MH  - Cell Survival
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/diagnosis/*metabolism/surgery
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Proportional Hazards Models
MH  - Protein Structure, Tertiary
MH  - RNA/*biosynthesis
MH  - RNA, Messenger/metabolism
MH  - Receptors, Retinoic Acid/*physiology
MH  - Retinoid X Receptors
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Time Factors
MH  - Transcription Factors/*physiology
MH  - Treatment Outcome
EDAT- 2002/02/13 10:00
MHDA- 2002/05/29 10:01
CRDT- 2002/02/13 10:00
PHST- 2002/02/13 10:00 [pubmed]
PHST- 2002/05/29 10:01 [medline]
PHST- 2002/02/13 10:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 2002 Feb;8(2):438-43.